Stockscreener 앱 받기
1.13
3.67%
0.04
시장 영업 전:
1.13
전일 마감가:
$1.09
열려 있는:
$1.12
하루 거래량:
3.65M
Relative Volume:
0.37
시가총액:
$235.77M
수익:
$176.23M
순이익/손실:
$-257.83M
주가수익비율:
-0.7687
EPS:
-1.47
순현금흐름:
$-246.00M
1주 성능:
+10.24%
1개월 성능:
-54.25%
6개월 성능:
+184.56%
1년 성능:
+161.51%
1일 변동 폭
$1.07
$1.15
1주일 범위
$1.05
$1.15
52주 변동 폭
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
1.13 | 235.77M | 176.23M | -257.83M | -246.00M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - News & Insights
Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN
Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL
WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - AccessWire
15 Small-Cap Stocks Poised to Outperform in 2025 - Insider Monkey
Sangamo to regain rights to hemophilia A gene therapy - Hemophilia News Today
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect - AccessWire
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More - Zacks Investment Research
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - PR Newswire
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership - MSN
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com India
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive
Sangamo Therapeutics’ SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com Nigeria
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal - MSN
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership - MM+M Online
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation - AccessWire
Sangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwright - MarketBeat
Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer - Contract Pharma
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership - Barron's
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact - BioSpace
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Sangamo Therapeutics: Left At The Alter (Rating Downgrade) - Seeking Alpha
Sangamo stock plunges as Pfizer leaves hemophilia partnership - BioWorld Online
Jefferies Financial Group Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $3.00 - MarketBeat
Options run thin for Sangamo Therapeutics after Pfizer deal crashesSan Francisco Business Times - San Francisco Business Times
Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Hemophilia Treatment Partnership - MSN
9 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing - MedCity News
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends Hemophilia pact - MSN
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemop - GuruFocus.com
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact - MarketWatch
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):